Hip FracturesMOB-SCORENCT07622095
Validation of the French Version of the New Mobility Score (NMS)
An observational study of Hip Fractures and Mobility Limitation, run by Hospices Civils de Lyon at 1 site in France.
Trial summary
The incidence of hip fractures in France is 50,000 cases per year among women and 16,000 among men, with a 1-year mortality rate of 20-24%. After a fracture, 10-30% of patients become functionally dependent. Read more about this study
- Who is it for?
- Ages 75 years and older
- Conditions the study is for
- Hip Fractures, Mobility Limitation, Independence
- What is being tested?
- Questionnaires
- How many people
- 100 participants
- Where
- 1 siteFrance
- Study dates
- 27 Aug 2026to Mar 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 75 years and older
- All sexes
- Older adult
Study population: Subjects admitted to a hospital ward following a hip fracture
Who may be able to join
- Patients aged 75 years and older admitted to a hospital department following a hip fracture and treated surgically (osteosynthesis or arthroplasty).
- Type of fracture: pertrochanteric fracture or femoral neck fracture.
- Sufficient proficiency in French to complete the questionnaires.
- Patients affiliated with a health insurance scheme.
- No objection to participate from the patient or the caregiver in case of cognitive impairment.
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Service I3 de court séjour gériatrique, Hôpital de la Croix-Rousse, Hospices Civils de Lyon
Lyon, 69004
Iago HUGHES SANMARTIN, Physiotherapist, (0)4 26 10 94 75 ext. +33, Iago.hughes-sanmartin@chu-lyon.fr
Iago HUGHES SANMARTIN, Physiotherapist
About this study
Official title: Validation of the French Version of the New Mobility Score (NMS) in Hospitalized Patients With Hip Fracture
The incidence of hip fractures in France is 50,000 cases per year among women and 16,000 among men, with a 1-year mortality rate of 20-24%. After a fracture, 10-30% of patients become functionally dependent. The increasing aging of the population and the rise in dependency are likely to worsen the situation of older patients in hospital settings.
Several tools are available to assess functional independence, including the New Mobility Score (NMS), which evaluates mobility through three domains: mobility indoors, mobility outdoors, and shopping activities. The NMS has shown good performance in predicting patient mortality and functional recovery, and its use is recommended in clinical practice. However, the French version of the NMS has not yet been validated.
The French validation of the NMS is important to facilitate its implementation in clinical practice and research, particularly because of its simplicity and the need for rapid assessment tools for healthcare professionals. A French version of the NMS has been translated, and the MOB-SCORE study aims to assess its reliability and validity among healthcare professionals caring for patients with hip fractures.
- Conditions
- Hip Fractures, Mobility Limitation, Independence, Autonomy
- Being tested
- Questionnaires
- Keywords
- New Mobility Score, Validation, Inter-rater reliability
- Medical subject headings
- Hip Fractures, Mobility Limitation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QuestionnairesOther
New Mobility Score (NMS), Measure of Functional Independence (MIF), Cumulated Ambulation Score (CAS), Mini-Mental State Examination (MMSE).
| Study group | Role | What they receive |
|---|---|---|
| Subjects aged 75 years and over admitted to a hospital ward following a hip fracture | Subjects aged 75 years and over, admitted to a hospital service following a hip fracture (per trochanteric or femoral neck) and having received surgical treatment (osteosynthesis or arthroplasty). Receives: Other: Questionnaires |
What is being measured
The primary outcome is the main question the study is designed to answer.
Inter-rater reliability of the New Mobility Score (NMS)
The New Mobility Score (NMS) assesses mobility in three domains (indoors, outdoors, and while shopping). For each domain, a score ranging from 0 (unable to perform the task) to 3 (able to perform the task independently) is assigned, with a total score ranging from 0 to 9. A score of ≤6 indicates functional impairment, whereas a score of >6 indicates a high pre-fracture level of mobility in patients with hip fracture. The NMS will be rated by a physiotherapist and an adapted physical activity (APA) instructor.
Measured: Within 7 days following the fracture surgery
Secondary outcomes (4)
Internal consistency of the New Mobility Score (NMS)
Internal consistency of the New Mobility Score (NMS) items.
Measured: Within 7 days following the fracture surgery
Convergent validity of the New Mobility Score (NMS) with other functional independence scales, cognitive status and age.
Correlation between the New Mobility Score (NMS) and:
- Measure of Functional Independence (MIF): 18 items assessing 6 functional domains. Each item is scored from 1 (total assistance) to 7 (complete independence). The total score ranges from 18 to 126.
- Cumulated Ambulation Score (CAS): independence in 3 activities (getting in and out of bed, sitting down and rising from a chair, walking ability). Each activity is scored on a scale from 0 (unable despite human assistance) to 2 (able without human assistance), with a total score ranging from 0 to 6 (6 indicating independent ambulation).
- Mini-Mental State Examination (MMSE): 30 questions divided into 6 categories. For each question, a correct answer scores 1 point (0 otherwise), with a total score ranging from 0 to 30.
- Age
Measured: Within 7 days following the fracture surgery
Predictive validity of mortality at postoperative day 30.
Correlation between the New Mobility Score (NMS) and vital status at postoperative day 30.
Measured: Within 30 days following the fracture surgery
Discriminatory validity based on place of residence.
Comparison of the New Mobility Score (NMS) according to pre-fracture living arrangements: living alone versus living in a nursing home/with family.
Measured: Within 7 days following the fracture surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jun 2026
- Study start27 Aug 2026
- Primary completionFeb 2028 (estimated)
- Study completionMar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hip FracturesStudies of the same condition, open and under way.
- More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospices Civils de Lyon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07622095
- Sponsor's protocol ID
- 69HCL25_0571
- Acronym
- MOB-SCORE
- Status last verified
- Sep 2026
- First submitted
- 28 May 2026
- Last updated
- 3 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Validation of the French Version of the New Mobility Score (NMS) in Hospitalized Patients With Hip Fracture
- ClinicalTrials.gov ID
- NCT07622095
- Acronym / sponsor ID
- MOB-SCORE / 69HCL25_0571
- Conditions
- Hip Fractures, Mobility Limitation, Independence, Autonomy
- Keywords
- New Mobility Score, Validation, Inter-rater reliability
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Hospices Civils de LyonUniversity, hospital or other
- Study start
- 27 Aug 2026 (actual)
- Primary completion
- Feb 2028 (estimated)
- Study completion
- Mar 2028 (estimated)
- First posted
- 2 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The incidence of hip fractures in France is 50,000 cases per year among women and 16,000 among men, with a 1-year mortality rate of 20-24%. After a fracture, 10-30% of patients become functionally dependent. The increasing aging of the population and the rise in dependency are likely to worsen the situation of older patients in hospital settings.
Several tools are available to assess functional independence, including the New Mobility Score (NMS), which evaluates mobility through three domains: mobility indoors, mobility outdoors, and shopping activities. The NMS has shown good performance in predicting patient mortality and functional recovery, and its use is recommended in clinical practice. However, the French version of the NMS has not yet been validated.
The French validation of the NMS is important to facilitate its implementation in clinical practice and research, particularly because of its simplicity and the need for rapid assessment tools for healthcare professionals. A French version of the NMS has been translated, and the MOB-SCORE study aims to assess its reliability and validity among healthcare professionals caring for patients with hip fractures.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Subjects aged 75 years and over admitted to a hospital ward following a hip fracture | – | Other: QuestionnairesSubjects aged 75 years and over, admitted to a hospital service following a hip fracture (per trochanteric or femoral neck) and having received surgical treatment (osteosynthesis or arthroplasty). |
Who may qualify
- Ages
- 75 years and older
- Sex
- All
- Age groups
- Older adult
- Study population
- Subjects admitted to a hospital ward following a hip fracture
Key inclusion criteria (5 listed)
- Patients aged 75 years and older admitted to a hospital department following a hip fracture and treated surgically (osteosynthesis or arthroplasty).
- Type of fracture: pertrochanteric fracture or femoral neck fracture.
- Sufficient proficiency in French to complete the questionnaires.
- Patients affiliated with a health insurance scheme.
- No objection to participate from the patient or the caregiver in case of cognitive impairment.
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| QuestionnairesNew Mobility Score (NMS), Measure of Functional Independence (MIF), Cumulated Ambulation Score (CAS), Mini-Mental State Examination (MMSE). | Other | Subjects aged 75 years and over admitted to a hospital ward following a hip fracture |
Primary outcome
Inter-rater reliability of the New Mobility Score (NMS)
Time frame: Within 7 days following the fracture surgery
The New Mobility Score (NMS) assesses mobility in three domains (indoors, outdoors, and while shopping). For each domain, a score ranging from 0 (unable to perform the task) to 3 (able to perform the task independently) is assigned, with a total score ranging from 0 to 9. A score of ≤6 indicates functional impairment, whereas a score of >6 indicates a high pre-fracture level of mobility in patients with hip fracture. The NMS will be rated by a physiotherapist and an adapted physical activity (APA) instructor.
4 secondary outcomes
Internal consistency of the New Mobility Score (NMS)
Time frame: Within 7 days following the fracture surgery
Convergent validity of the New Mobility Score (NMS) with other functional independence scales, cognitive status and age.
Time frame: Within 7 days following the fracture surgery
Predictive validity of mortality at postoperative day 30.
Time frame: Within 30 days following the fracture surgery
Discriminatory validity based on place of residence.
Time frame: Within 7 days following the fracture surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Sep 2026.
Related trials for Hip Fractures
Not yet recruitingPhase 4
Effect of Ondansetron on the Incidence of Spinal Anaesthesia-Induced Hypotension in Elderly Patients Undergoing Fracture Hip Surgery
Spinal Anaesthesia Induced Hypotension
Not yet recruiting
Lumbar Erector Spinae Plane Block Versus PENG Block for Hip Fracture Surgery
Femur Neck Fracture, Hip Fractures
Active, not recruiting
Lumbar-Sacral Plexus Block vs Fascia Iliaca Block Plus Low-Dose Spinal Anesthesia for Femoral Neck Fracture Surgery
Femoral Neck Fractures, Nerve Block
RecruitingObservational study
Real World Evidence of SI-BONE's iFuse TORQ TNT Advancing Treatment of Pelvic Ring Fractures
Fracture; Pelvic, Insufficiency Fractures
Not yet recruiting
A Decision Support Tool for Common Surgical Fixations of Hip Fractures
Hip Fracture Surgeries, High Risk Population of Hip Fractures
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hip Fractures and Mobility Limitation, run by Hospices Civils de Lyon at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Olivia FEBVEY-COMBES, MD ((0)4 72 11 51 62 ext. +33, olivia.febvey-combes@chu-lyon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Inter-rater reliability of the New Mobility Score (NMS) (time frame: Within 7 days following the fracture surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2026.